



WO 02/30495 A2



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

- 1 -

PEN DEVICE FOR ADMINISTRATION OF PARATHYROID HORMONE

BACKGROUND OF THE INVENTION

This invention relates to devices and methods for the administration of parathyroid hormone (PTH). PTH is a secreted, 84 amino acid product of the mammalian parathyroid gland that controls serum calcium levels through its action on various tissues, including bone. The N-terminal 34 amino acids of bovine and human PTH (PTH(1-34)) is deemed 5 biologically equivalent to the full length hormone. Other amino terminal fragments of PTH (including 1-31 and 1-38 for example), or PTHrP (PTH-related peptide/protein) or 10 analogues of either or both, that activate the PTH/PTHrP receptor (PTH1 receptor) have shown similar biologic effects 15 on bone mass, although the magnitude of such effects may vary.

PTH and PTH fragments can be administered by 20 subcutaneous injection using a conventional syringe-and-vial system, wherein the liquid PTH solution is manually drawn up from a vial using a syringe. However, it is often difficult to draw up the correct amount of liquid using conventional 25 syringes.

Because most osteoporotics are of advanced age, a simple step-by-step procedure for dosing PTH is needed.

- 2 -

SUMMARY OF THE INVENTION

A need exists to provide the osteoporotic patient with a convenient and simple administration device that allows for the daily dosing of a single, predetermined fixed dose 5 of PTH. The present invention accomplishes this by providing a pen-type injection device designed so that only a single predetermined dose is easily set. Moreover, the present invention involves a pen device containing a reservoir of PTH and a simple step-by-step method for 10 administering the PTH that virtually eliminates the concern of over or under dosing. By practicing the invention, PTH is easily administered and results in increased toughness or stiffness at a site of a potential trauma, such as a hip or spine of a person with osteoporosis, or at another site 15 having abnormally low bone mass or poor bone structure.

The present invention provides a pen-type injection or delivery device and a method for administering a single predetermined dose of a solution containing parathyroid hormone. The inventive device is in the general shape of a 20 writing pen having a reservoir containing a solution of PTH. The elongate, compact shape of the pen delivery device facilitates the use of simple injection techniques and allows the patient to easily carry the device on his/her person. The pen device is designed so that only a single 25 predetermined dose is easily set by the patient using a rotatable dose knob attached to the proximal end of the pen. This dose knob can be dialed in both a forward and reverse direction without causing a dose to be delivered. Although the dose knob freely rotates, only one priming position and 30 one dose position is easily set. By having only one dose setting, this greatly simplifies the procedure for administering an injection of PTH. Moreover, having only a

- 3 -

single dose setting greatly reduces the possibility of a patient under dosing or overdosing himself or herself.

In one embodiment of the invention, the pen device is disposable and has a reservoir of PTH permanently fixed 5 within the injector body. When the reservoir of PTH is exhausted the entire device is simply thrown away. This reservoir may consist of a glass cartridge permanently sealed within the injector body. In another embodiment, the pen is reusable and the reservoir comprises a replaceable 10 cartridge. Once the PTH in the cartridge is expelled through multiple injections, the empty cartridge is removed from the pen and a new cartridge filled with fresh PTH solution is placed in the injector body. In all cases, the pen is designed so that the pen needle is easily removed by 15 the user facilitating single use of the needle.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a perspective view of one embodiment of a pen delivery device in accordance with the present invention;

20 FIG. 2 is an exploded view of the device of FIG. 1;

FIG. 3 is an enlarged perspective view of a portion of the pen device of FIG. 1, particularly showing the dose knob and housing components;

25 FIG. 4 is an enlarged longitudinal sectional view of a portion of the medication dispensing device of FIG. 1, particularly showing the button assembly disposed within dose knob;

FIG. 5 is an enlarged perspective view, in partial section, of the medication dispensing device of FIG. 1, 30 particularly showing the button assembly disposed in the dose knob;

FIG. 6 is an enlarged cross sectional view of the

- 4 -

medication dispensing device of FIG. 1, particularly showing the insufficient remaining dose stop on the nut approaching the corresponding stop on the leadscrew;

FIG. 7 is a view of FIG. 6, except that the
5 insufficient remaining dose stop on the nut is in engagement
with the stop on the leadscrew;

FIG. 8 is a perspective view, in partial section, of a housing part in engagement with the dose knob, particularly showing the unit click finger in the zero position;

10 FIG. 9 is a view of FIG. 8, except that the unit click finger is behind the end-of-dose flange;

FIG. 10 is a view of FIG. 8, except that the unit click finger is shown in the dial splines during dosing;

15 FIG. 11 is an enlarged sectional view of a portion of the medication dispensing device of FIG. 1, particularly showing the relationship among the button assembly, dose knob, and housing while the device is at the end of dose position;

20 FIG. 12 is a longitudinal sectional view of the medication dispensing device of FIG. 1, particularly showing the dose knob after it has been rotated to the zero position;

25 FIG. 13 is a view of FIG. 12 except that the dose knob has been retracted so that the splines of the nut are engaged by the splines of the dose knob;

FIG. 14 is a view of FIG. 13, except that a desired dosage has been dialed up;

30 FIG. 15 is a view similar to FIG. 11, showing the dose knob rotated 180°, and further showing the button initially depressed before dial movement takes place;

FIG. 16 is a view of FIG. 15, showing the dial having moved forward a small distance;

- 5 -

FIG. 17 is a view of FIG. 15, showing the dial having moved forward half of a thread pitch; and

FIG. 18 is a view of FIG. 14, except that the pen is shown in its end-of-dose position.

5

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The pen device of the present invention is generally illustrated in FIG. 1. The pen device 10 is in the shape of a standard writing pen and has a clip 15 attached to cap 16, which allows the pen to be securely fastened to a pocket or other carrying means. Cap 16 protects the pen needle 23, as illustrated in FIG. 2, and provides access to the reservoir or cartridge 22. To achieve the single dosing feature of the invention, the injector body of the pen device is designed with a hard stop. Although it is not critical where in the pen device the hard stop is located, it must, however, be positioned such that the dose knob 11 cannot be rotated outwardly to a position where the pen will deliver a dose greater than a predetermined single maximum dosage. In the situation where PTH is being prescribed to treat osteoporosis, a set single daily dose of 80 μ L has been determined to be effective. Preferably, the hard stop is positioned in either housing 20 or 14 of the injector body and more specifically it is located within threads 43, which are located on the interior portion of both housing 20 and 14. Placing the hard stop within threads 43 ensures that dose knob 11 is prevented from advancing outwardly a distance more than that required to deliver a predetermined single dose. As described in more detail below, the dose knob, after dialing it outwardly to a preset position, is pushed inwardly causing drive stem 21 to advance forward in

- 6 -

the distal direction causing the solution of PTH to be expelled through the pen needle.

To further ensure that only a single accurate dose is delivered to the patient, the dose knob 11 of the pen device 5 is calibrated and visibly marked with a single priming position indicator and a single predetermined injectable dose position indicator. This calibration and marking of the dose knob is a significant departure from existing pen delivery devices typically used for insulin or human growth 10 hormone delivery. Those existing devices are characterized in that they can deliver a great number of different dosages depending on where the patient or health care provider dials the dose knob. Moreover, the dose knobs of those existing devices are marked and calibrated in International Units, 15 typically having up to 80 different possible dose settings. In contrast, the administration of PTH typically requires only a single, predetermined, non-varying dose on a daily basis. Accordingly, device 10 is not marked with International Units, but instead with three discrete step 20 indicators. Preferably these steps indicators are printed on the dose knob as "0," "1," and "2." These step indicators are illustrated in FIG. 3 by numeral 40. Step indicators "1" and "2" correspond to a predetermined priming dose and an injectable dose, respectively.

25 In addition to the pen device, the invention also is directed to a method or procedure for performing an injection of PTH. That method involves rotating the dose knob 11 until an arrow ("→") 41, or other identifying symbol, printed on the dose knob 11 is visible to the 30 patient through lens 12 in housing 14. Once the arrow is in position, dose knob 11 can be pulled outwardly (towards the proximal end of the pen) until the first step or starting

- 7 -

position is reached, designated by the "0" visible through lens 12. The "0" step indicator signals the user that dial knob 11 of the pen device is correctly positioned to continue the procedure for delivering a single predetermined dose of PTH. Step designations "0," "1," and "2" are printed on dose knob 11 and viewed by the patient through lens 12. After the "0" starting position is reached, the patient further rotates the dose knob 11 until the priming position is reached. A printed "1" appears in the lens designating that the second position has been reached. The user then pushes on disengaging device 17 to cause the dose knob and drive stem to move inwardly (towards the distal end of the pen) expelling a small amount of PTH from the needle. Typically, the priming dose is predetermined to be approximately 10-20 μ L. The priming dose is an important step in the method because it allows the patient to verify that the pen is working properly and that the pen needle is positioned correctly and not clogged or obstructed.

Once priming is completed, the next step in the method involves repeating the first two steps of rotating the dial knob 11 until the arrow ("→") 41 comes into view in lens 12, pulling the knob outward until the "0" is visible and then rotating the dose knob past the "1" indicator position to the third and last position, designated by the number "2." Although it is preferred to use Arabic numerals, any logical sequence of symbols, such as Roman numerals or letters will provide the necessary visual feedback to the end user signaling the three positions. As with the priming position, the injectable dose position is predetermined and corresponds to a dose which is customary for the treatment of a specific disorder using PTH. In the case of osteoporosis, it is common to prescribe a daily dose of

- 8 -

80 μ L. As mentioned, to ensure that the injectable dose does not exceed the predetermined quantity of PTH, the pen device is designed with a hard stop that prevents the dose knob from being dialed outwardly past the "2" position. The 5 exact location or design of the hard stop is not critical to the invention, as long as the dose knob is prevented from rotating past the predetermined injectable dose position. A preferred hard stop is one that is placed within threads 43 of either housing 20 or 14 as illustrated in FIGS. 2 and 3 10 by numeral 44. The hard stop can be made of any material that will stand up to repetitive contact with finger 19 of dose knob 11. In operation of the pen device, finger 19 engages threads 43 located inside housings 14 and 20 allowing the dose knob 11 to move inwardly and outwardly as 15 it is rotated from the "0" position. As the dose knob is rotated outwardly, finger 19 eventually will come into contact with hard stop 44, thus preventing any further rotation. Preferably, hard stop 44 is made of the same plastic material that is used to construct the housings. 20 The exact positioning of the hard stop within the threads is selected so that the dose knob, using the dose knob, cannot be rotated outwardly past injectable dose position "2."

Once position "2" is reached, the patient is ready to insert pen needle 23 into the injection site. The pen 25 needle of device 10 can be any type of pen needle known to the art, typically comprising a double-ended needle, 27G or smaller diameter, fixed in hub 50 that can be easily screwed on and off the distal end of the pen assembly. A preferred size of pen needle 23 is within the range of 29G to 31G. 30 After insertion of the pen needle, the patient depresses disengaging device 17. When disengaging device 17 is pushed inwardly, dose knob 11 and drive stem 21 also move inwardly

- 9 -

in a linear direction towards the distal end of the pen device. As drive stem 21 moves inwardly it pushes on a piston 210 (see Figs. 12 -14) within the reservoir containing the PTH solution, shown in FIG. 2 as cartridge 22. As the piston is pushed by drive stem 21 towards the distal end, it causes the solution of PTH to be expelled through pen needle 23. To signal the end-of-dose, the invention provides both visual and tactile indicators. The visual indicator is viewed by the patient through lens 12, 10 as a distinct end-of-dose symbol, such as a diamond shape ("◊") 42, which is printed on the dose knob. If the patient does not see the symbol he knows to continue pushing on the disengaging device 17. The tactile indicator comprises a second hard stop, which is the point of contact between the 15 dose knob 11 and the bulkheads 45 on housings 14 and 20. The contact between the dose knob and the bulkheads on the housings prevents further travel of the drive stem and provides a tactile feel to the patient indicating the dose is complete.

20 The invention also contains a mechanism that will prevent the dose knob from being rotated to injectable dose position "2" if there is an insufficient solution of PTH remaining within the reservoir of the pen device. This feature is accomplished by predetermining the distance the 25 drive stem must travel to deliver the contents of the reservoir. In the case where a glass cartridge is used as a reservoir, typically this would be about 3 mL. Of course, this volume is dependant on the cartridge's dimensional tolerances and can vary accordingly. The drive stem is 30 designed with only a sufficient number of threads to allow the dose knob to dial and deliver a discreet number of doses. Since the dose knob moves towards the distal end of

- 10 -

the threads on the drive stem 21 as the dose knob 11 is rotated outwardly to set a dose, and the drive stem is prevented from moving backward after each injection by anti-backup features, which are described more fully below, the 5 dose knob gets closer to the end of the drive stem's threads with each injection. When the amount of starting PTH solution has been expelled, the drive stem will be at the end of its threads. To further illustrate this feature, consider the example where the reservoir has only 40 μ L of 10 PTH solution remaining after an injection, and the user attempts to perform another injection of 80 μ L. Following the administration procedure, the following would occur. The user would be able to correctly perform the steps through the priming position "1," however, they would not be 15 able to rotate the dose knob to the third position "2," this is because only 20 μ L remain in the reservoir (40 μ L - 20 μ L (priming dose)). Since the threads on the drive stem correspond to the volume of PTH solution remaining in the reservoir, no further travel of the dose knob about the 20 threads of the drive stem is possible, hence no further rotation of the dose knob is possible. As such, the user is unable to rotate the dose knob to a position where the "2" is visible, thus signaling the user that the pen device is not properly set for administration of the correct 25 predetermined dose. At this point, the user would either discard the pen, if it was disposable, or would replace the cartridge with a full one.

FIGS. 4-18 provide a more detailed and specific mechanical configuration of the pen device and for purposes 30 of this application, the term "proximal" shall designate a relative axial position toward the knob end of the delivery mechanism, and the term "distal" shall designate a relative

- 11 -

axial position toward the delivery needle end of the delivery mechanism. All of the components of medication device 10, except cartridge 22 and needle 23 may be made of a plastic material that is suitable for recycling. Suitable 5 plastics include high flow polycarbonates resins, which can be processed by conventional injection molding and extrusion. In one embodiment, the housing parts 14, 20 and distal body 42 are made from an optically clear polycarbonate material, and the remaining plastic components 10 are made from ABS resins. These plastics are recyclable, thereby making disposal of the device environmentally desirable.

Referring to FIG. 5, disengaging device 17 comprises a hollow cylindrical portion 48 having a proximal end. 15 Cylindrical portion 48 includes a distal end 52 in the form of an annular bead and further includes an enlarged diameter ring 54 comprising an enlarged diameter flat surface 58. The inner section of surface forms an enlarged diameter shoulder surface 60. Proximal end of disengaging device 17 further 20 includes a finger-engageable end 68 having a recessed surface 70. End 68 is integrally connected to hollow cylindrical portion 48 by connection portions 72 (FIG. 4). Proximal end 51 includes a surface 74 (FIG. 4) that is formed from reduced length portion 76.

25 Referring to FIGS. 4 and 11, dose knob 11 is shown in detail. Dose knob 11 is generally cylindrical in shape and is hollow throughout its axial length. The diameter of dose knob 11 is at a maximum at its proximal end and is at a minimum at its distal end. Referring to FIG. 4, dose knob 11 30 comprises a proximal portion 78, an intermediate portion 80, and a distal portion 82. Proximal portion 78 comprises an enlarged diameter portion 84, a tapered portion 86, and an

- 12 -

end-of-dose ring 91 extending about the circumference of proximal portion 78 as shown in FIG. 4. Ring 91 includes a bottom surface 89 (FIG. 14) that constitutes a stop surface when engaged with the rear of the housing. Ring 91 also 5 includes an enlarged "zero-dose" protrusion 88. The proximal inner surface of flexible section 92 includes a tapered surface 96 adapted for engagement with tapered surface 56 of disengaging device 17 and a corresponding tapered surface 98. Surfaces 96 and 98 define the inner surface of finger 10 94.

Proximal portion 78 of dose knob 11 further includes a first U-shaped groove 100 (FIG. 4) and a second U-shaped groove (not shown) which form flexible legs 102, 104.

Referring to FIG. 11, each leg 102, 104, includes an 15 inwardly extending finger 106, 108, and an outwardly extending finger 110, 112, distal to the inwardly extending finger. Inwardly extending finger 106 includes proximal tapered surface 114, flat 116, and distal tapered surface 118. Likewise, finger 108 includes proximal tapered surface 20 120, flat 122, and distal tapered surface 124. Outwardly extending finger 110 comprises a proximal tapered surface 126, a flat 128, shoulder 130, enlarged diameter surface 132, and distal tapered surface 134. Outwardly extending finger 112 includes a proximal tapered surface 136, a 25 shoulder 138, an enlarged diameter surface 140, and a distal tapered surface 143.

Referring to FIG. 4, a series of axial splines 142 are arranged circumferentially about the inner surface of dose knob 11 at the area where proximal portion 78 meets 30 intermediate portion 80. The circumferential array of splines 143 is interrupted by legs 102 and 104. In one embodiment, there are ten splines 143 positioned about the

- 13 -

inner circumference of dose knob 11. Referring to FIGS. 3 and 11, there is shown a plurality of splines 144 extending circumferentially about the proximal interior surface of intermediate portion 80 of dose knob 18. Unlike splines 143, 5 splines 144 extend 360° about the inner circumference of intermediate portion 80. In one embodiment, eighteen splines 144 are positioned such that each spline is 20 circumferential degrees apart from an adjacent spline.

As best shown in FIGS. 8-10, distal portion 82 of dose 10 knob 11 comprises a proximal flange 146, a reduced diameter portion 148, and a distal end comprising a series of elongated splines 150 extending externally about the circumference of distal portion 82. Splines 150 are in alignment with splines 144. Therefore, in one embodiment, 15 there are eighteen splines 150, each corresponding to a respective spline 144. As shown in FIGS. 9 and 10, two of the splines 150 extend axially into reduced diameter portion 148. These extensions are indicated as splines 152.

Referring to FIG. 11, housing parts 14 and 26 form a 20 proximal groove 154 having a tapered surface 156. Housing parts 14 and 20 further form a helical spiral groove 158 and a tapered circumferential surface 160 as shown in FIG. 11. Housing part 14 further includes a semicircular ridge 164 near the distal end thereof. Housing part 20 includes 25 grooves formed therein to define a flexible leg 168 having an inwardly extending finger 170 at the end thereof. Finger 170 includes a proximal tapered surface 172, which terminates in a flat 174 and a vertical edge 176. Housing parts 14 and 20 include transverse ledges 178, 180, 30 respectively, to reduce the diameter through the proximal end of the housing. Ledges 178 and 180 include flexible tangs 182, 184, respectively.

- 14 -

As best shown in FIGS. 12-14 and 18, pen device 10 further includes nut 36 and drive stem 21. Nut 36 is generally cylindrical in shape and includes a pair of axially extending grooves 186 (FIG. 2) to form resilient proximal legs 188. Each leg 188 includes a proximal raised portion 190 and two small axially extending splines 192 (FIG. 12). The distal end of nut 36 comprises an enlarged gear-like member 194 having a plurality of teeth 196 thereon. The interior surface of the distal end of nut 36 includes a helical thread 198. Thread 198 extends about 350° about the inner surface of nut 36. A groove 200 is formed at the distal end of drive stem 21 to form legs 226, 228 (FIG. 2). Ratchet teeth 204 are located on two opposing sides of drive stem 21 and axially extend along the length of drive stem 21 from groove 200 to the distal end, which constitutes plunger engagement portion 206. Helical threads 208 extend along the axial length of drive stem 21 legs 226, 228. Drive stem 21 fits within the cylindrical opening of nut 36.

As shown in FIGS. 12-15, plunger engagement portion 206 of drive stem 21 is in engagement with piston 210 of cartridge 22. Cartridge 22 is housed within cartridge retainer 42, which is permanently secured to housing parts 14 and 20. Cartridge 22 is manufactured of glass and comprises a tube defining an inner chamber 212 which openly terminates at its distal end in a neck 214 having a cap 216 including a rubber disc 218 disposed thereover. Needle assembly 23 comprises an internally threaded base 220 and a delivery needle 222. Internally threaded base 220 is threaded onto externally threaded distal portion 224 of body 42. Needle cap 46 fits over needle 222 to prevent an inadvertent insertion of needle 222 into the patient. Cap 16

- 15 -

snaps onto cartridge body 42 to complete the pen-like mechanism.

As described above, in order to set a dose for injection, it is first necessary to manually zero the dial from the initial radial position of the dial resulting from the previous injection. The initial axial position of dose knob 11, in a non-zero initial radial position with respect to housing part 20 is shown in FIG. 9. Specifically, finger 170 of housing part 20 is located in groove 148 of dose knob 11. Groove 148 can be rotated by rotating dose knob 11 with respect to the housing. Dose knob 11 cannot be axially retracted due to the interference between a first element on the dose metering mechanism, i.e., ledge 149 of dose knob 11, and a second element on the housing, i.e., vertical edge 176 of housing finger 170. Likewise, dose knob 11 cannot be forced axially forwardly due to the interference between surface 89 on ring 91 and end surfaces 33, 35 (FIG. 5) of housing parts 14, 20, respectively. If the user mistakenly believes that it is necessary to depress disengaging device 17 to pull out the dial, finger 94 falls into groove 154 (FIG. 11), thereby creating an interference that prevents the dial from being pulled out. Upon continued rotation of dose knob 11 with respect to housing 20, splines 152 are moved into engagement with finger 170, as shown in FIG. 8. This is the zero dose radial position of dose knob 11. This radial zero dose position is communicated to a user in four ways. The user hears a click as splines 152 engage finger 170. The movement of finger 170 over the first spline 152 into the V-shaped recess 155 between splines 152 causes a vibration in device 10 that can be felt by the user. In addition, protrusion 88 on dose knob 11 is in axial alignment with protrusion 153 of housing part 14, thereby

- 16 -

providing a visual indication that the zero dose position has been reached. This is further visually communicated by the presence of an arrow symbol 41 in lens 12.

A series of numerals ("0", "1" and "2") are printed on 5 the surface of intermediate portion 80 of dose knob 11. These numerals are helically spaced about the circumference of portion 80 as illustrated in FIG. 3. The lens 12 in housing part 14 is aligned with the numbers so that the appropriate number appears in the lens upon dialing up 10 either the prime or the single dosage. A raised rectangular portion 162 (FIG. 11) of lens 12 is located at the base of lens 12 to enhance the numerals thus making them easier to read.

When the initial position is reached and the arrow 41 15 is visible, dose knob 11 may be axially retracted a predetermined distance, e.g. 3 to 5 mm, as illustrated in FIG. 13 for a dose to be set. As dose knob 11 is retracted, ledge 149 is moved past housing finger 170 resulting in 20 housing finger 170 being in engagement with splines 150. In addition, splines 144 of dose knob 11 are moved into engagement with splines 192 of nut 36, as shown in FIG. 13. When dose knob 11 is in a dose-setting position the clutch mechanism comprised of splines 144 and 192 is engaged and 25 rotation of dose knob 11 causes corresponding rotation of nut 36. Rotation of drive stem 21 is prevented by a key-keyway type of engagement between the anti-backup tangs 182 and 184 and drive stem 21. As shown in FIG. 7, tangs 182, 184 form a key, and drive stem 21 forms a keyway which comes into contact with the sides of the key.

30 Upon rotation of dose knob 11 to a positive dose radial position, fingers 110, 112 move within housing groove 158 in the proximal direction to retract dose knob 11, thereby

- 17 -

increasing the axial distance between stop surface 89 of ring 91 and stop surfaces 33, 35 of housing parts 14, 20. Rotation of dose knob 11 causes rotation of nut 36 so that internal helical raised groove 198 of nut 36 rotates along 5 external threads 208 of drive stem 21 to cause nut 36 to axially retract a corresponding axial distance. As shown in FIG. 10, rotation of dose knob 11 causes splines 150 to move past housing finger 170. As each spline 150 moves past finger 170, it causes a "click" to occur, thereby providing 10 an audible indication as the priming or dose setting is reached.

Once the priming setting has been set, cap 16 is removed and needle cover 46 is removed to expose needle 222. The needle is pointed upward, and recessed surface 70 of 15 disengaging device 17 is pushed to perform an air shot to prime the pen, with the pushing of recessed surface 70 causing the pen to mechanically operate as described more fully below with respect to the dose injecting. Specifically, after the air shot priming, once the dose 20 setting has been set, the needle is inserted into the patient, and recessed surface 70 of disengaging device 17 is pushed. FIGS. 15-17 illustrate the initial stages of the injection process. Referring to FIG. 15, as surface 70 is pushed, disengaging device 17 moves forwardly independently 25 of dose knob 11 until button distal surface 52 bottoms out against internal dial shoulder 141. Thereafter, disengaging device 17 and dose knob 11 are moved together. Referring to FIG. 16, as dose knob 11 begins to move forwardly, tapered finger surfaces 134, 142 are forced out of their respective 30 threads 158. This causes fingers 110, 112 to flex radially inwardly. As disengaging device 17 is further pressed, fingers 110, 112 move out of respective threads 158, as

- 18 -

shown in FIG. 15. As disengaging device 17 continues to be pressed, fingers 110, 112 move into and out of the remaining threads 158 in a like manner until dial 18 reaches its end of dose position shown in FIGS. 11 and 18. The movement of 5 edge 95 (FIG. 4) of dial finger 94 past housing edge 157 (FIG. 5) and into groove 154 (FIG. 11) creates an audible "click" sound, thereby providing an audible confirmation that the priming dose or the injectable dose has been completed. Finger 94 is in close proximity to stop surfaces 10 89 and 33, 35. Thus, as described above, it is the non-rotational axial advancement of the dosage metering mechanism, which drives the drive stem and thereby delivers the selected dosage.

As dose knob 11 is initially moved forwardly the 15 clutching mechanism comprised of splines 144 and 192 decouples as splines 144 move out of engagement with splines 192 of nut 36 to rotatably disengaged dose knob 11 from nut 36 prior to any axial movement of nut 36. Dose knob 11 moves axially with respect to nut 36 until the distal end 193 20 (FIG. 14) of dose knob 11 engages nut flange 194 and moves nut 36 and drive stem 21 forwardly to deliver the set dosage of fluid.

Referring to FIGS. 11 and 18, forward movement of dose knob 11 and nut 36 is limited by the engagement of surface 25 89 of ring 91 with proximal end surfaces 33, 35 of housing parts 14, 20, respectively, as shown in FIG. 15. Referring to FIG. 15, there is a small clearance, e.g. 0.4 millimeters, between nut gear or flange 194 and internal ledges 178, 180 of housing parts 14, 20, respectively. In 30 another embodiment, the end-of-dose stop may be designed to occur between nut flange 194 and ledges 178, 180.

- 19 -

Movement of drive stem 21 is prevented in the proximal direction due to anti-backup tangs 182, 184 being in engagement with ratchet teeth 204. This assures that head 206 of drive stem 21 remains at all times in constant 5 engagement with piston 210.

Once a dosage has been completed, the user releases his finger from recessed surface 70. Upon releasing pressure from surface 70, the flexible fingers or springs 62, 64 return from their stressed conditions back to their relaxed 10 conditions, thereby automatically retracting the disengaging device 17 back to the automatic lockout position shown in FIG. 12 to prevent the dose knob 11 from being inadvertently advanced when it is again moved to its retracted position.

As discussed, the inventive pen device and the method 15 of its use incorporates a reservoir containing a solution of PTH. As active ingredient, the composition or solution may incorporate the full length, 84 amino acid form of parathyroid hormone, particularly the human form, hPTH (1-84), obtained either recombinantly, by peptide synthesis or 20 by extraction from human fluid. The composition or solution may also incorporate as active ingredient fragments or variants of fragments of human PTH or of rat, porcine or bovine PTH that have PTH activity.

The parathyroid hormone fragments desirably incorporate 25 at least the first 28 N-terminal residues, such as PTH(1-28), PTH(1-31), PTH(1-34), PTH(1-37), PTH(1-38) and PTH(1-41). Alternatives in the form of PTH variants incorporate from 1 to 5 amino acid substitutions that improve PTH stability and half-life, such as the replacement of 30 methionine residues at positions 8 and/or 18 with leucine or other hydrophobic amino acid that improves PTH stability against oxidation and the replacement of amino acids in the

- 20 -

25-27 region with trypsin-insensitive amino acids such as histidine or other amino acid that improves PTH stability against protease. Other suitable forms of PTH include PTHrP, PTHrP(1-34), PTHrP(1-36) and analogs of PTH or PTHrP 5 that activate the PTH1 receptor. These forms of PTH are embraced by the term "parathyroid hormone" as used generically herein. The hormones may be obtained by known recombinant or synthetic methods.

A preferred hormone for use in the invention is human 10 PTH(1-34), also known as teriparatide. This particular PTH can be used as stabilized solutions of human PTH(1-34). A stabilized solution of a parathyroid hormone can include a stabilizing agent, a buffering agent, a preservative, and the like. The stabilizing agent incorporated into the 15 solution or composition includes a polyol which includes a saccharide, preferably a monosaccharide or disaccharide, e.g., glucose, trehalose, raffinose, or sucrose; a sugar alcohol such as, for example, mannitol, sorbitol or inositol, and a polyhydric alcohol such as glycerin or 20 propylene glycol or mixtures thereof. A preferred polyol is mannitol or propylene glycol. The concentration of polyol may range from about 1 to about 20 wt-%, preferably about 3 to 10 wt-% of the total solution.

The buffering agent employed in the solution or 25 composition of the present invention may be any acid or salt combination which is pharmaceutically acceptable and capable of maintaining the aqueous solution at a pH range of 3 to 7, preferably 3-6. Useful buffering systems are, for example, acetate, tartrate or citrate sources. Preferred buffer 30 systems are acetate or tartrate sources, most preferred is an acetate source. The concentration of buffer may be in

- 21 -

the range of about 2 mM to about 500 mM, preferably about 2 mM to 100 mM.

The stabilized solution or composition of the present invention may also include a parenterally acceptable preservative. Such preservatives include, for example, cresols, benzyl alcohol, phenol, benzalkonium chloride, benzethonium chloride, chlorobutanol, phenylethyl alcohol, methyl paraben, propyl paraben, thimerosal and phenylmercuric nitrate and acetate. A preferred preservative is m-cresol or benzyl alcohol; most preferred is m-cresol. The amount of preservative employed may range from about 0.1 to about 2 wt-%, preferably about 0.3 to about 1.0 wt-% of the total solution. The stabilized teriparatide solution can contain mannitol, acetate and m-cresol with a predicted shelf-life of over 15 months at 5°C.

The parathyroid hormone is formulated for administering a dose effective for increasing toughness and/or stiffness of one or more of a subject's bones. Preferably, an effective dose provides an improvement in cortical bone structure, mass, and/or strength. An effective dose of hPTH(1-34) is typically greater than about 6 micrograms per day, preferably in the range of 15 to 65 micrograms per day, more preferably 20 to 40 micrograms per day. Doses of other PTH forms having equivalent activity in standard bioassays may also be used. A subject suffering from hypoparathyroidism can require additional or higher doses of a parathyroid hormone. Doses required for replacement therapy in hypoparathyroidism are known in the art.

The hormone can be administered regularly (e.g., once or more each day or week), intermittently (e.g., irregularly during a day or week), or cyclically (e.g., regularly for a period of days or weeks followed by a period without

- 22 -

administration). Preferably PTH is administered once daily for a period ranging from 3 months for up to 3 years in osteoporotic patients. Typically, the benefits of administration of a parathyroid hormone persist after a 5 period of administration. The benefits of several months of administration can persist for as much as a year or two, or more, without additional administration.

It will be appreciated by those skilled in the art that the foregoing is presented by way of illustration only, and 10 not by way of any limitation, and that various alternatives and modifications may be made to the illustrated embodiment without departing from the spirit and scope of the invention.

I claim:

1. A pen delivery device comprising;
a pen-shaped injector body having proximal and
5 distal ends and a reservoir within the injector body;
parathyroid hormone contained within the
reservoir;
a rotatable dose knob attached to the proximal end
of the injector body;
10 a pen needle removably attached to the distal end
of the injector body; and
wherein said injector body has a first hard stop
to prevent dose delivery of more than a preset single
maximum injectable dose of the parathyroid hormone.
- 15 2. The pen delivery device of Claim 1 where the pen
delivery device is disposable.
3. The pen delivery device of Claim 1 where the pen
delivery device is reusable.
4. The pen delivery device of Claim 1 where the
20 reservoir is a glass cartridge.
5. The pen delivery device of Claim 4 where the
cartridge is removable from the injector body.
6. The pen delivery device of Claim 4 where the
cartridge is permanently affixed within the injector body.
- 25 7. The pen delivery device of Claim 1 where the dose
knob can be dialed in both a forward and reverse direction
before dosing.
8. The pen delivery device of Claim 1 where the dose
knob has only one setting mark indicating delivery of said
30 preset single injectable dose of the parathyroid hormone.
9. The pen delivery device of Claim 1 having a
housing with threads in communication with a dose knob,

- 24 -

where said first hard stop is positioned in the threads to limit rotation of the dose knob.

10. The pen delivery device of Claim 9 where the dose knob is calibrated and marked with a predetermined priming 5 position and a predetermined injectable dose.

11. The pen delivery device of Claim 1 where the injector body has a second hard stop to signal completion of the injection.

12. The pen delivery device of Claim 1 wherein the 10 dose knob is marked with step designations corresponding to predetermined priming and injectable dosages.

13. The pen delivery device of Claim 1 wherein the parathyroid hormone is human PTH(1-34).

14. A method of using a single dose pen delivery 15 device for the administering of parathyroid hormone to a patient comprising,

providing a pen delivery device containing a solution of parathyroid hormone and a pen needle;

rotating a dose knob to a priming position 20 indicator located on the dose knob; pushing the dose knob to prime the pen delivery device;

rotating the dose knob to a hard stop position corresponding to an injectable dose indicator located on the 25 dose knob;

inserting the pen needle into the patient and injecting a predetermined injectable dose of the parathyroid hormone; and

removing the pen needle from the patient after 30 completing the injection.

- 25 -

15. A method of using a single dose pen delivery device as claimed in any of claims 1-13 for the administering of parathyroid hormone to a patient.

1/18




FIG. 1





FIG. 2

3/18

FIG. 3



4 / 18




FIG.

5/18




FIG. 5

6/18




FIG. 6

7/18





FIG. 7

8/18



88

9/18




FIG. 9

10/18






FIG. 10

11/18



12/18



13/18





FIG. 13

14/18



三
一
E
I
G
.

15/18




FIG. 15

16/18




FIG. 16

17/18





FIG. 17

18/18



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 April 2002 (18.04.2002)

PCT

(10) International Publication Number
WO 02/030495 A3

(51) International Patent Classification⁷: A61M 5/315,
5/24

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/US01/27732

(22) International Filing Date:
26 September 2001 (26.09.2001)

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
60/239,172 9 October 2000 (09.10.2000) US

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL,
SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR),
OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations


Published:

— with international search report

[Continued on next page]

(54) Title: PEN DEVICE FOR ADMINISTRATION OF PARATHYROID HORMONE

WO 02/030495 A3



(57) Abstract: A pen delivery device and a procedure for administering parathyroid hormone is provided to allow for the priming and injection of a single predetermined dose. The method is a three-step method using visual indicators to set the priming and injectable dose deliveries. The device is made of a minimal number of parts, which include a housing, a dose knob, a generally cylindrical disengaging assembly located within the proximal end of the dose knob, and an externally threaded drive stem. The pen device further includes a mechanism that prevents the user from dialing up a dosage greater than that remaining in the cartridge.



(88) Date of publication of the international search report:

4 July 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

II INTERNATIONAL SEARCH REPORT

Inte	onal Application No
PCT/US 01/27732	

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61M5/315 A61M5/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6 001 089 A (HIXSON DAVE ET AL) 14 December 1999 (1999-12-14) the whole document see especially column 7, lines 44,45 column 8, line 5 - line 20 column 9, line 5 - line 10 column 9, line 51 - line 54 ---	1-7,9-13
Y	WO 98 55168 A (LILLY CO ELI) 10 December 1998 (1998-12-10) page 3, line 18 - line 21 ---	1-7,9-13
A	EP 0 554 996 A (BECTON DICKINSON CO) 11 August 1993 (1993-08-11) column 7, line 42 - line 48 figures 10,11 ---	1 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

g document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

5 April 2002

12/04/2002

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Sedy, R

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/27732

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DE 41 12 259 A (MEDICO DEV INVESTMENT CO) 22 October 1992 (1992-10-22) column 6, line 56 - line 63 ---	1
A	DE 198 38 760 A (BAUER JLONA ;PRAEZISIONSTECHNIK UND ELEKTRO (DE)) 20 April 2000 (2000-04-20) column 3, line 51 - line 57 column 3, line 66 -column 4, line 1 column 4, line 12 - line 21 figure 1 -----	1,8

II INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte onal Application No
PCT/US 01/27732

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6001089	A 14-12-1999	AT 193833 T AU 696439 B2 AU 4863796 A CA 2213682 A1 DE 69608833 D1 DE 69608833 T2 DK 730876 T3 EP 0730876 A2 EP 0879610 A2 ES 2147346 T3 GR 3034256 T3 JP 2002503116 T NO 974073 A PT 730876 T SI 730876 T1 US 5938642 A WO 9627400 A1 US 6221046 B1 ZA 9601845 A	15-06-2000 10-09-1998 23-09-1996 12-09-1996 20-07-2000 30-11-2000 31-07-2000 11-09-1996 25-11-1998 01-09-2000 29-12-2000 29-01-2002 28-10-1997 30-11-2000 31-12-2000 17-08-1999 12-09-1996 24-04-2001 08-09-1997
WO 9855168	A 10-12-1998	AU 733383 B2 AU 7816798 A BR 9809929 A EP 1007115 A1 JP 2002502296 T NO 995964 A WO 9855168 A1	10-05-2001 21-12-1998 01-08-2000 14-06-2000 22-01-2002 03-12-1999 10-12-1998
EP 0554996	A 11-08-1993	US 5279585 A CA 2088110 A1 DE 69305376 D1 DE 69305376 T2 EP 0554996 A1 JP 1903543 C JP 5337179 A JP 6024599 B	18-01-1994 05-08-1993 21-11-1996 20-03-1997 11-08-1993 08-02-1995 21-12-1993 06-04-1994
DE 4112259	A 22-10-1992	DE 4112259 A1 AT 143610 T DE 59207292 D1 WO 9218179 A1 EP 0581788 A1 JP 2607817 B2 US 5591136 A	22-10-1992 15-10-1996 07-11-1996 29-10-1992 09-02-1994 07-05-1997 07-01-1997
DE 19838760	A 20-04-2000	DE 19838760 A1	20-04-2000